Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 25:10:118.
doi: 10.3389/fnagi.2018.00118. eCollection 2018.

The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease

Affiliations
Review

The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease

Holly M Brothers et al. Front Aging Neurosci. .

Abstract

Amyloid-ß (Aß) is best known as the misfolded peptide that is involved in the pathogenesis of Alzheimer's disease (AD), and it is currently the primary therapeutic target in attempts to arrest the course of this disease. This notoriety has overshadowed evidence that Aß serves several important physiological functions. Aß is present throughout the lifespan, it has been found in all vertebrates examined thus far, and its molecular sequence shows a high degree of conservation. These features are typical of a factor that contributes significantly to biological fitness, and this suggestion has been supported by evidence of functions that are beneficial for the brain. The putative roles of Aß include protecting the body from infections, repairing leaks in the blood-brain barrier, promoting recovery from injury, and regulating synaptic function. Evidence for these beneficial roles comes from in vitro and in vivo studies, which have shown that the cellular production of Aß rapidly increases in response to a physiological challenge and often diminishes upon recovery. These roles are further supported by the adverse outcomes of clinical trials that have attempted to deplete Aß in order to treat AD. We suggest that anti-Aß therapies will produce fewer adverse effects if the known triggers of Aß deposition (e.g., pathogens, hypertension, and diabetes) are addressed first.

Keywords: ARIA; antimicrobial; cancer; cerebrovascular; immune system; infection; seizure; traumatic injury.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Aß is antimicrobial against bacteria, fungi, and viruses. Aß has the mechanical properties to trap microbes, insert into and permeabilize their membranes, and create a toxic oxidative response that is likely accelerated in the presence of iron obtained from nearby ferritin-rich cells.
Figure 2
Figure 2
Aß seals leaky vessels. Traumatic brain injury and cerebrovascular insults stimulate Aß production and draw Aß to the vasculature. Aß binds to red blood cells (RBCs), blood proteins, and to iron (Fe) and copper (Cu) ions. These interactions cause Aß to aggregate at the site of hemorrhage or breaches of the BBB. Aß anchors into cell membranes and increases adherence between RBCs and vascular endothelial cells, helping to seal leaks in the vasculature.

Similar articles

Cited by

References

    1. Abramowski D., Wiederhold K.-H., Furrer U., Jaton A.-L., Neuenschwander A., Runser M.-J., et al. . (2008). Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J. Pharmacol. Exp. Ther. 327, 411–424. 10.1124/jpet.108.140327 - DOI - PubMed
    1. Abu Hamdeh S., Waara E. R., Möller C., Söderberg L., Basun H., Alafuzoff I., et al. . (2017). Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injury. Brain Pathol. [Epub ahead of print]. 10.1111/bpa.12532 - DOI - PMC - PubMed
    1. Acosta S. A., Tajiri N., Sanberg P. R., Kaneko Y., Borlongan C. V. (2017). Increased amyloid precursor protein and tau expression manifests as key secondary cell death in chronic traumatic brain injury. J. Cell. Physiol. 232, 665–677. 10.1002/jcp.25629 - DOI - PMC - PubMed
    1. Aisen P. S., Gauthier S., Vellas B., Briand R., Saumier D., Laurin J., et al. . (2007). Alzhemed: a potential treatment for Alzheimer's disease. Curr. Alzheimer Res. 4, 473–478. 10.2174/156720507781788882 - DOI - PubMed
    1. Aisen P. S., Saumier D., Briand R., Laurin J., Gervais F., Tremblay P., et al. . (2006). A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67, 1757–1763. 10.1212/01.wnl.0000244346.08950.64 - DOI - PubMed